CURE & YALE University: Yale BioHaven Enterprenurship

Tuesday, February 12, 2008 Rib-X Pharmaceuticals, Inc. Followed by networking, refreshments & wine bar Rib-X Pharmaceuticals, Inc. is focused on the design and development of novel small-molecule antibiotics for the treatment of antibiotic-resistant infections in hospital and community settings. Since its inception in 2001, Rib-X has established a portfolio of development and discovery-stage compounds that address various segments in the diverse antibiotic marketplace, including RX-3341, a broad spectrum quinolone antibiotic which will soon enter Phase 3 studies as an IV agent and RX-1741, an oxazolidinone antibiotic now in two Phase 2 studies as an oral agent. Many classical antibiotics work by inhibiting the function of the ribosome. A key competitive advantage for Rib-X is its proprietary access to the high-resolution crystal structure of the ribosome, a molecule which is essential for the viability of all bacterial pathogens and the target of numerous valuable antibiotics. Rib-X's research goal is to use chemical and physical information from the three-dimensional structure of the ribosome to design proprietary classes of antibacterial agents that have activity against newly emerging multiple antibiotic-resistant microorganisms. Structural and computational data about how ligands block the function of this complex molecular machine are being used to prime parallel lead optimization programs focused on new chemistry ideas about the multiple binding domains or drug targets within the ribosome. The scope of the Rib-X structure based design process will enable the Company to fully exploit the chemistry of the ribosome and build a pipeline of diverse products and as a result a sustainable franchise. Rib-X raised $50 million in a Series C Preferred Stock financing announced in June of 2006. The round was led by existing investor Warburg Pincus, the global private equity investment firm. That round of financing brought the total amount raised by the company to $123 million. Speakers Susan Froshauer, Ph.D. President & Chief Executive Officer, Rib-X Pharmaceuticals, Inc. Erin Duffy, Ph.D. Vice President, Structure Based Drug Design, Rib-X Pharmaceuticals, Inc. Tuesday, February 12, 2008 3:30 P.M. Registration 4:00 P.M. Seminar 5:00 P.M. Networking, Refreshments & Wine Bar Location The Anlyan Center auditorium, Yale Medical School. Directions & Parking: http://info.med.yale.edu/maps/cab.html RSVP Registration is free, but please RSVP in advance. E-mail to biohaven@yale.edu or call the Yale OCR main number: 203-785-6209. Mark Your Calendar The next seminar in the series, on March 19, 2008, features Optherion, Inc. Download a brochure of the complete 2007-2008 series here. Lead sponsors: Wiggin and Dana and PricewaterhouseCoopers. Also sponsored by Elm Street Ventures. Presented by CURE and the Yale Office of Cooperative Research. Additional support from the Yale Entrepreneurial Society and the Yale Biotechnology & Pharmaceutical Society. Published by Connecticut United for Research Excellence Copyright © 2008 Connecticut United for Research Excellence. All rights reserved. Visit CURE at http://curenet.org and BioBus Educational Programs at http://ctbiobus.org TELL A FRIEND

Powered by IMN™ this e-mail was sent to drmuni From Connecticut United for Research Excellence, 300 George Street, New Haven, CT 06511 USA